Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus
GuanQun Liu and Michaela U Gack

The outbreak of the COVID-19 pandemic one year after the centennial of the 1918 influenza pandemic reaffirms the catastrophic impact respiratory viruses can have on global health and economy. A key feature of SARS-CoV-2 and influenza A viruses (IAV) is their remarkable ability to suppress or dysregulate human immune responses. Here, we summarize the growing knowledge about the interplay of SARS-CoV-2 and antiviral innate immunity, with an emphasis on the regulation of type-I or -III interferon responses that are critically implicated in COVID-19 pathogenesis. Furthermore, we draw parallels to IAV infection and discuss shared innate immune sensing mechanisms and the respective viral countermeasures.

Address
Cleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL, USA

Corresponding author: Michaela U Gack (gackm@ccf.org)

Introduction
Respiratory viruses such as coronaviruses and influenza A viruses (IAV) can cause significant morbidity and mortality in the human population, as evidenced by the ongoing COVID-19 pandemic and the past influenza pandemics in the 20th century and in 2009. Early clinical symptoms of upper respiratory infections by SARS-CoV-2 and antiviral innate immunity, with an emphasis on the regulation of type-I or -III interferon responses that are critically implicated in COVID-19 pathogenesis. Furthermore, we draw parallels to IAV infection and discuss shared innate immune sensing mechanisms and the respective viral countermeasures.

Interferon dysregulation and its role in COVID-19 pathogenesis
The important role of type-I/III IFNs in COVID-19 pathogenesis has been recognized at the onset of the pandemic. Early studies indicated that SARS-CoV-2 infection impaired IFN production but induced an overzealous proinflammatory response in vitro and in patient peripheral blood, which likely accounted for the CSS observed in severe disease [3•–5]. Longitudinal and single-cell transcriptomics studies however found elevated and sustained expression of type-I/III IFNs and/or ISGs in bronchoalveolar lavage fluid or peripheral
blood in severe COVID-19 compared with mild cases [6–9]. Interestingly, whereas patients with IAV infection mount robust type-I/-III IFN and proinflammatory responses from illness onset on and regardless of disease severity, COVID-19 patients did not produce IFNs until days 7–10 after symptom onset [10•]. This delayed IFN production combined with prolonged inflammation distinguishes COVID-19 from other known respiratory viral infections and likely underlies the unique pathogenicity of SARS-CoV-2 [7,10•].

The identification of neutralizing autoantibodies against type-I IFNs in a proportion of critically ill COVID-19 patients confirms the importance of IFN-mediated immunity in SARS-CoV-2 pathogenesis [11]. The presence of preexisting autoantibodies does not appear to preclude these patients to severe viral infections other than SARS-CoV-2, indicating a key role for an effective early type-I IFN response in influencing COVID-19 progression. In accordance, the IFN/ISG levels in the nasal mucosa and blood during early SARS-CoV-2 infection coincided with viral loads in mild illness, but not with those in critically ill patients harboring anti-IFN autoantibodies [11].

Mounting evidence shows efficient early SARS-CoV-2 replication in the nasopharynx, despite induction of type-I/-III IFNs and/or ISGs [12,13]. The inability of the initial wave of antiviral IFN responses to efficiently restrict SARS-CoV-2 has also been corroborated in studies using human airway and intestinal epithelial cell cultures and organoids [13–15], which showed that robust viral replication precedes peaks of IFN and ISG induction. This delayed antiviral IFN response can drive immunopathology via pulmonary recruitment and activation of proinflammatory immune cells and lung injury [9,16]. This phenomenon has also been observed in mouse models of SARS-CoV, MERS-CoV, and IAV infection [17]. On the other hand, early IFN/ISG responses elicited by coinfection with rhinovirus or IAV can substantially block SARS-CoV-2 replication [13–15], indicating that delaying IFN responses represents a major strategy of immune evasion by SARS-CoV-2.

**Innate immune sensing of SARS-CoV-2 and influenza A viruses**

Various families of PRRs mediate the detection of respiratory viral infections and the ensuing induction of type-I/-III IFNs and proinflammatory cytokines. Once activated by viral or host-derived ligands, these sensors trigger signaling through distinct adaptor proteins and a set of common transcription factors, such as IFN-regulatory factors (IRFs) and nuclear factor kappa B (NF-κB) [19]. SARS-CoV-2, a member of the family *Coronaviridae*, contains a positive-sense RNA genome of ~30 kb and replicates via a mechanism of continuous and discontinuous RNA synthesis that produces long double-stranded RNA (dsRNA) species during infection. In contrast, replication of the segmented negative-sense RNA genome of IAV (an orthomyxovirus) does not generate detectable amounts of long dsRNA. As such, coronavirus and IAV are generally perceived as virus prototypes that are sensed respectively by MDA5 and RIG-I, two founding members of the RIG-I-like receptor (RLR) family that typically detect cytoplasmic ‘nonself’ dsRNA with length preference. While RIG-I binds preferentially blunt-ended short dsRNA bearing a 5′-triphosphate moiety such as the IAV (sub)genomic panhandle structure, MDA5 associates with complex long dsRNA whose precise characteristics remain still elusive (Figure 1) [20]. Several studies have demonstrated that type-I/-III IFN induction by SARS-CoV-2 relies on MDA5, with RIG-I contributing little to this process [21••,22•]. However, RIG-I was found to exert IFN-independent antiviral activity by competing with the viral polymerase for binding to the 3′-untranslated region (UTR) of the SARS-CoV-2 genomic RNA [23•]. Of note, similar mechanisms of signaling-independent virus restriction by RIG-I have also been reported for other viruses including IAV [24]. Interestingly, in contrast to RIG-I, MDA5 preferentially binds negative-strand SARS-CoV-2 RNA during infection [23•], suggesting that active viral replication is required for triggering MDA5 activation and that both MDA5 and RIG-I may contribute to SARS-CoV-2 restriction in a temporal manner.

Besides RLRs, Toll-like receptors (TLRs) and cGAS also play crucial roles in the sensing of SARS-CoV-2 infection (Figure 1). Genetic studies revealed that inborn deficiency in TLR3 and TLR7 signaling underlies defective type-I IFN production and severe disease in a group of COVID-19 patients [25,26•]. TLR7-mediated type-I IFN responses in plasmacytoid dendritic cells reportedly play a critical role in protection against severe COVID-19 [27], while uncontrolled TLR7 activation can lead to CSS in severe influenza [28]. cGAS activation following mitochondrial DNA (mtDNA) release during SARS-CoV-2 infection was shown to elicit aberrant IFN production, which causes IFN-mediated immunopathology in severe COVID-19 [29••].

Downstream of IFNs, certain ISGs and their effector functions are also implicated in innate restriction and immunomodulation during SARS-CoV-2 infection (Figure 1). A splice variant of 2′-5′-oligoadenylate synthetase 1 (OAS1), which undergoes prenylation in its unique carboxyl-terminus, anchors to SARS-CoV-2-replication organelles and senses the 5′-UTR of viral RNA, which ultimately activates RNase L-mediated restriction [30••]. An intrinsic single-nucleotide polymorphism that influences the expression of the prenylated OAS1 isoform was associated with disease
Induction and antagonism of type-I/-III IFN responses by SARS-CoV-2 and IAV. Type-I/-III IFN induction by SARS-CoV-2 relies primarily on MDA5, which senses long dsRNA species. MDA5 then undergoes a series of PTMs, including ISGylation in its caspase activation and recruitment domains (CARDs), oligomerizes, and translocates to the mitochondrion where it interacts with and activates MAVS. MAVS recruits downstream signaling molecules such as TBK1/IKKe and the IKKα/β/γ complex that subsequently activate transcription factors, including IRF3 and NF-κB. Upon translocation from the cytoplasm to the nucleus, these transcription factors drive the expression of type-I/-III IFNs and proinflammatory cytokines, which, once secreted, prompt autocrine and paracrine signaling in infected and bystander cells, respectively. Specifically, type-I/-III IFNs engage cognate IFN receptors that signal through the JAK–STAT axis to upregulate ISGs. Besides MDA5, the cGAS–STING pathway (via released mtDNA), as well as TLR3 and TLR7, are also implicated in SARS-CoV-2 sensing possibly in a cell-type-specific manner, though the mechanistic details require further investigation. These sensing pathways activate similar downstream kinases and transcription factors, leading to type-I/-III IFN gene expression. A prenylated OAS1 isoform, which anchors to the endoplasmic reticulum-derived double-membrane vesicles (DMVs) where SARS-CoV-2 replication takes place, restricts virus replication by activating RNase L. RIG-I exerts an IFN-independent restriction mechanism by competing with the SARS-CoV-2 polymerase for binding to the 3′-UTR of the viral genome (not depicted). Likewise, during IAV infection, RIG-I binds to the genomic RNA panhandle structure associated with the IAV polymerase, which can impede viral replication in an IFN-independent manner (not illustrated). In many cell types (except plasmacytoid dendritic cells for example), IFN induction by IAV is primarily or exclusively dependent on RIG-I. Upon recognition of the IAV (sub)genomic panhandle structure, RIG-I undergoes conformational changes and PTMs such as activating K63-linked polyubiquitination in its CARDs and C-terminal domain (CTD) by TRIM25 and Riplet, respectively. RIG-I then activates an analogous signaling pathway as MDA5 to induce antiviral immunity. To evade immune surveillance, IAV uses the NS1 protein as the primary IFN antagonist. NS1 binds to TRIM25 and Riplet, thereby inhibiting the K63-linked polyubiquitination of RIG-I in the cytoplasm. NS1 also localizes to the nucleus where it blocks polyadenylation and nuclear export of cellular mRNAs via binding to the cellular cleavage and polyadenylation factor 30 (CPSF30). This host-shutoff strategy is believed to act in concert with another host-shutoff mechanism carried out by IAV PA-X protein, which selectively degrades host RNA polymerase II (Pol II) transcripts via its endonucleolytic activity. The IAV PB1–F2 protein binds to MAVS at the mitochondrion and suppresses MAVS activation by decreasing the mitochondrial membrane potential. Like IAV, SARS-CoV-2 targets critical PTMs of innate sensors and downstream signaling molecules to antagonize IFN responses. The PLpro activity of Nsp3 actively removes conjugated ISG15 from MDA5 and IRF3 to suppress their activation. Furthermore, extracellular secretion of free ISG15 prompted by PLpro’s de-ISGylating activity can exacerbate proinflammatory cytokine responses. Nsp5 cleaves and disables RIG-I and also induces MAVS degradation. Nsp1 plugs the mRNA entry tunnel of the 40S ribosomal subunit to shut off host-protein translation. Nsp14 and Nsp16 also reportedly disturb host translation and transcription processes, though the precise mechanisms are still unknown. Nsp14 and Nsp16 catalyze Cap-1 modification of viral RNA to mimic host mRNA and escape recognition by MDA5. Nsp15 of murine hepatitis virus and likely also SARS-CoV-2 cleaves and limits the accumulation of viral dsRNA to evade MDA5 sensing. Orf9b competes with the chaperone protein Hsp90 for binding to TOM70 and thereby impairs the recruitment of TBK1 and IRF3 (both associated with Hsp90) to the TOM70–MAVS complex. Orf6 interacts with the nuclear pore complex Nup98–Rae1 and impedes the nuclear import of IRF3 and STAT1/2. Orf3a, Orf7a/b, M, and N also reportedly dampen STAT1/2 and/or MAVS activation; the underlying mechanisms, however, require further investigation. SARS-CoV-2 proteins inhibiting IFN/ISG responses are depicted in pink. IAV proteins blocking innate immune signaling are illustrated in orange. ‘Ub’ indicates ubiquitin.
severity in a patient cohort [30••], making it a potential prognostic marker for severe COVID-19. ISG15, which exists in both a free and a conjugated version (the latter mediating protein ISGylation), was found to be secreted from macrophages infected with SARS-CoV-2 [31•]. Extracellular ISG15 then functions ‘cytokine-like’ by inducing proinflammatory responses in a paracrine manner, likely contributing to hyperinflammation in COVID-19 [31•].

**Interferon antagonism by SARS-CoV-2 and influenza A viruses**

Effective viral antagonism of type-I/-III IFN induction requires the spatiotemporal coordination of multiple viral proteins that target distinct steps in antiviral signal transduction. This sophisticated operation perhaps is mastered best by SARS-CoV-2 encoding ~30 viral proteins, many of which exhibit immunomodulatory activities when ectopically expressed [32•]. While extensive research has established a central role for the IAV non-structural protein 1 (NS1) in innate immune evasion (Figure 1) [33], the strategies used by SARS-CoV-2 proteins to antagonize IFN-mediated antiviral immunity have just begun to be elucidated. Among the non-structural proteins of SARS-CoV-2 that have immunosuppressive functions, Nsp1 binds to the mRNA channel of the human 40S ribosomal subunit and thereby globally interferes with the translation of host antiviral gene transcripts such as IFNs and ISGs [34••,35]. Additionally, Nsp1 induces host mRNA degradation and impedes the nuclear export of host mRNA [36]. Nsp14 and Nsp16 also dysregulate host translation and transcription processes, including splicing, though the precise mechanisms remain elusive [35,37]. It is possible that specific SARS-CoV-2 proteins contribute temporally to host shutoff during infection, which would mirror the coordinated action of IAV’s NS1 and PA-X proteins in mediating host shutoff (Figure 1) [38].

At least four nonstructural proteins of SARS-CoV-2 target the RLR pathway to antagonize type-I/-III IFN induction (Figure 1). Being the largest multidomain coronavirus protein, Nsp3 is a key component of the viral RNA-synthesis machinery. In addition, Nsp3 has immunomodulatory activity, which is primarily attributable to its papain-like protease (PLpro) domain. PLpro is known to enzymatically remove from substrates covalently conjugated polyubiquitin or ISG15, thereby subverting antiviral-signaling proteins that require for their activation ubiquitination or ISGylation. ISGylation recently emerged as a key activation mechanism for the initiation of MDA5-mediated antiviral signaling by promoting MDA5 higher-order assemblies. This activation step is counteracted by SARS-CoV-2 via PLpro-mediated de-ISGylation of MDA5 [21••]. Downstream of MDA5 and other PRRs, PLpro also removes ISGylation from IRF3, thereby suppressing IFN induction [39••]. Moreover, dysregulation of the cellular ratio of free versus conjugated ISG15 by SARS-CoV-2 PLpro was shown to lead to aberrant macrophage activation and proinflammatory cytokine production [31•]. Targeting essential posttranslational modifications (PTMs) in RNA sensors is also well-characterized for IAV NS1, which, however, does not possess catalytic activity itself. NS1 binds to and inhibits the ubiquitin E3 ligases TRIM25 and Riplet to prevent activating K63-linked polyubiquitination of RIG-I, thereby blunting antiviral signaling [40,41]. The SARS-CoV-2 main protease, Nsp5, was found to cleave and inactivate RIG-I and to induce degradation of the mitochondrial antiviral-signalining protein (MAVS), the shared downstream adaptor protein for RIG-I and MDA5 [42]. Several coronaviruses, including SARS-CoV-2, also modify viral RNA ligands to evade recognition by MDA5. The viral 2’-O-methyltransferase Nsp16, together with the N7 methyltransferase activity of Nsp14, catalyzes Cap-1 modification of viral RNA to mimic host mRNA, thereby escaping detection by MDA5. In accordance, inhibiting viral and cellular methyltransferase activities during SARS-CoV-2 infection elevated antiviral gene expression and restricted viral replication [43•]. The endoribonuclease activity of Nsp15 can cleave and limit the accumulation of polyuridine-containing negative-sense viral RNAs activating MDA5 during mouse hepatitis virus infection [44]; whether an analogous immune-escape mechanism is utilized by SARS-CoV-2 requires further exploration.

SARS-CoV-2 accessory and structural proteins, which are expressed from viral subgenomic RNAs, also target key signaling hubs in the IFN pathway (Figure 1). Orf9b interacts with TOM70 at the mitochondrion and disrupts the recruitment of TANK-binding kinase 1 (TBK1) to MAVS [45]. Notably, the IAV PB1–F2 protein similarly targets MAVS at mitochondria to inhibit IFN induction [46]. SARS-CoV-2 Orf6 binds to nuclear pore complexes and blocks the cytoplasmic-to-nuclear translocation of IRF3 and STAT1/2 [47•]. Other viral proteins, such as Orf3a, Orf7a/b, M, and N, also appear to interfere with STAT phosphorylation and/or MAVS activation [48], however, the mechanistic details and physiological relevance of these evasion strategies require further investigation. Interestingly, compared with the ancestral strains, the Alpha variant of SARS-CoV-2 expresses notably higher levels of Orf6, Orf9b, and N proteins, which contributes to the enhanced immunosuppression of this variant and provides evolutionary evidence for the importance of these viral proteins in IFN antagonism [49••]. Moreover, profound IFN-mediated attenuation of a recombinant mutant SARS-CoV-2 was only seen when Orf3a was removed in addition to deletion of Orf6, Orf7, and Orf8 [50], suggesting a major role of Orf3a in manipulating antiviral IFN responses. Additionally, this
studies underscore the necessity of evaluating the relative contribution of viral proteins to innate immune evasion through the engineering of recombinant viruses using reverse genetics.

**Concluding remarks**

The sophisticated immunomodulatory abilities of SARS-CoV-2 and IAV, combined with their capacity to adapt to new host species, allow these viruses to cause outbreaks or pandemics. Despite the global efforts over the past two-and-a-half years in understanding COVID-19 pathogenesis, the mechanisms underlying the protective versus pathogenic role of type-I/III IFNs have just begun to be elucidated. More detailed insights into the strategies by which individual SARS-CoV-2 proteins rewire antiviral IFN responses are warranted to develop interventions that may help restore the protective functions of IFNs. Deciphering the specific interactions of SARS-CoV-2 with host innate immune proteins will also guide the rational design of live-attenuated vaccines that may mediate effective and long-lasting immunity.

**Conflict of interest statement**

The authors declare no conflicts of interest.

**Acknowledgements**

We apologize to all whose work could not be cited due to space constraints. Current research in the Gack laboratory is supported by National Institutes of Health Grants DP1 AI169444, R37 AI087846, R01 AI165502, R01 AI148534, and R01 AI127774, and an award from the “Where There is Light Foundation”.

**References and recommended reading**

Papers of particular interest, published within the period of review, have been highlighted as:

• of special interest

•• of outstanding interest.

1. Flavell RA, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S: Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol 2021, 19:425-441.

2. Fajgenbaum DC, June CH: Cytokine storm. N Engl J Med 2020, 383:2255-2273.

3. Blasco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K, Panis M, Sachs D, et al.: Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020, 181:1036-1045 e1039.

This study is among the first ones showing hyperinflammation and blunted type I/III IFN responses during SARS-CoV-2 infection.

4. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Pere H, Charbit B, Bondet V, Chenevier-Gobeaux C, et al.: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020, 369:718-724.

5. Combes AJ, Courau T, Kuhn NF, Hu KH, Roy A, Chen WS, Chew NW, Cleary SJ, Kathoorn D, Reeder GG, et al.: Global absence and targeting of protective immune states in severe COVID-19. Nature 2021, 591:124-130.

6. Broggi A, Ghosh S, Sposito B, Sprefaico R, Balzarini L, Coia C, Clementi N, De Santis M, Mancini N, Granucci F, et al.: Type III interferons disrupt the lung epithelial barrier upon viral infection. Science 2020, 369:706-712.

7. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, Choi B, Nam SK, Sa M, Kwon JS, et al.: Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol 2020, eabd1554.

8. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellington MK, Mao T, Oh JE, Israelev B, et al.: Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020, 584:463-469.

9. Sposito B, Broggi A, Pandolfi L, Crotsa S, Clementi N, Ferrarese R, Sisti S, Criscuolo E, Sprefaico R, Long JM, et al.: The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 2021, 184:4953-4968 e4916.

10. Galani IE, Rovina N, Lampropoulou V, Triantafyllia V, Manioudaki M, Pavlos E, Koukaki E, Fragiou PC, Panou V, Rapiti E, et al.: Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol 2021, 22:32-40.

This comparative study reveals key temporal cytokine patterns that distinguish severe COVID-19 from severe influenza.

11. Merad M, Blith CA, Iwasaki A: The immunology and immunopathology of COVID-19. Science 2022, 375:1122-1127.

12. Lopez J, Mommert M, Mouton W, Pizzorno A, Boussier J, Smith N, Pere H, Blish CA, Iwasaki A: Impaired type I interferon response of human plasmacytoid dendritic cells to SARS-CoV-2 infection by an NFkappaB-dependent mechanism. Sci Immunol 2020, eabd1554.

13. Cheron ML, Watkin JS, Hanevold BC, Zhao D, Wang G, Landry ML, Foxman E: Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. J Exp Med 2021, 218:e20201241.

14. Hatton CF, Botting RA, Duenas ME, Haq IJ, Verdon B, Thompson BJ, Ferretti JJ, Schmidt T, Hartmann R, Wack A: Role of toll-like receptors in the pathogenesis of SARS-CoV-2 infection. Cell Host Microbe 2021, 20:32-40.

15. Thorne LG, Reuschl AK, Zuliani-Alvarez L, Whelan MVX, Turner J, Nouradessahi M, Joly C, Towers GJ: SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J 2021, 40:e107826.

16. Israelov B, Song E, Mao T, Lu P, Meir A, Liu F, Afjaro MM, Wei J, Dong H, Homer RJ, et al.: Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med 2020, 217:e20201241.

17. Major J, Crotta S, Lorfan M, McCabe TM, Gao HH, Priestnall SL, Hartmann R, Wack A: Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 2020, 369:712-717.

18. Oishi K, Horuchi S, Minkoff JM, tenOever BR: The host response to influenza A virus interferes with SARS-CoV-2 replication during coinfection. J Virol 2022, 96:e0076222.

19. Liu G, Gack MU: Distinct and orchestrated functions of RNA sensors in innate immunity. Immunity 2020, 53:26-42.

20. Rehwinkel J, Gack MU: RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol 2020, 20:537-551.

21. Liu G, Lee JH, Parker ZM, Acharya D, Chiang JJ, van Gent M, Riedl W, Davis-Gardner ME, Wies E, Chiang C, et al.: ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat Microbiol 2021, 6:467-478.

This study unravels ISGylation as an essential PTM governing MDA5 activation, which is, in turn, counteracted by the delISGylating activity of the papain-like protease of SARS-CoV-2.

22. Yin X, Riva L, Pu Y, Martin-Sancho L, Kanaune J, Yamamoto Y, Sakai K, Gotoh S, Miorin L, De Jesus PD, et al.: MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 2021, 34:108628.

This study is among the first ones showing that MDA5 is the primary innate immune sensor of SARS-CoV-2.

23. Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, Yamauchi H, Sasaki M, Takakoa A: RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat Immunol 2021, 22:820-828.

This study reveals an IFN-signaling-independent role of RIG-I in restricting SARS-CoV-2 replication.

24. Weber M, Sediri H, Felgenhauer U, Binzen I, Banfer S, Jacob R, Brunotte L, Garcia-Sastre A, Schmidt-Burgk JL, Schmidt T, et al.: Influenza virus adaptation PB2-627K modulates antiviral immunity inhibition by the pathogen sensor RIG-I. Cell Host Microbe 2015, 17:309-319.
Innate immunity

25. Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Magnirolli Renklar AJRL, Zhang P, Meertens L, Bolze A, Materna M, et al.: X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 2021, 6:eab43348.

26. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabil IKD, Hodeib S, Korol C, et al.: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020, 369:eaaz570.

This study is among the primary genetic analyses identifying key loss-of-function mutations in genes that are involved in IFN pathways as potential determinants of severe COVID-19.

27. van der Sluis RM, Cham LB, Gris-Oliver A, Gammelgaard KR, Pedersen JG, Idorn M, Ahmadov U, Hernandez SS, Ormanovic E, Godzik SH, et al.: TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J 2022, 41:e109622.

28. Rapepe JCF, Finsterbusch K, Crotta S, Mack M, Priestnall SL, Wack A: A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. J Exp Med 2021, 218:e20201631.

This study uncovers a prenylated isoform of OAS1 that senses and restricts SARS-CoV-2 in the viral replication organelles, and further, that a single-nucleotide polymorphism controlling its expression may underly COVID-19 disease susceptibility and severity.

29. Domizio JD, Gulen MF, Saifoune F, Thacker VV, Yatin A, Sharma K, **Nass T, Guenova E, Schaller M, Conrad C, et al.: The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature 2022, 603:145-151.

This study reveals that sustained IFN production via activation of the cGAS-STING signaling axis by SARS-CoV-2 is a key driver of cell and tissue damage in COVID-19 immunopathology.

30. Wickenhagen A, Sugue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, Loney C, Herder V, Allan J, Jarmson I, et al.: A prenylated dsRNA sensor protects against severe COVID-19. Science 2021, 374:eab36304.

31. Muniru D, Teo Q, Eggertmont D, Lee HHY, Thery F, Ho J, van Leur SW, Ng WWS, Siu LYL, Beling A, et al.: Altered ISGylation drives aberrant macrophage-type dependent immune responses during SARS-CoV-2 infection. Nat Immunol 2021, 22:1416-1427.

This study shows that perturbation of free versus conjugated ISG15 in macrophages by SARS-CoV-2 Prf1 drives aberrant macrophage activation and ISG15 secretion that together lead to overzealous proinflammatory cytokine responses.

32. Gordon DE, Jiang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al.: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020, 583:459-468.

This study represents one of the first omics studies that depict the interactome of SARS-CoV-2 proteins in host cells and the associated cell signaling pathways that could be targeted for antiviral therapies.

33. Ayllon J, Garcia-Sastre A: The NS1 protein: a multitasking virulence factor. Curr Top Microbiol Immunol 2015, 386:73-107.

34. Thoms M, Buschauer R, Ameismeier M, Koepcke L, Denk T, **Hirschberger M, Kratzer H, Hayn M, Mackens-Kian T, Cheng J, et al.: Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 2020, 369:1249-1255.

This study provides detailed structural insights into the mechanism by which SARS-CoV-2 Nsp1 protein, through blocking the mRNA entry tunnel of the ribosomal small subunit, induces host translation shutdown.

35. Banerjee AK, Blanco MR, Bruce EA, Honson DD, Chen LM, Chow A, Bhat P, Olikkainen N, Quinodoz SA, Loney C, et al.: SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 2020, 183:1325-1339 e1321.

36. Finkel Y, Gluck A, Nachshon A, Winkler R, Fisher T, Rozman B, Mizrahi O, Lubelski Y, Zuckerman B, Slobodin B, et al.: SARS-CoV-2 uses a multipartitioned strategy to impede host protein synthesis. Nature 2021, 594:240-245.

37. Hsu JC, Laurent-Rolle M, Pavlak JB, Wilen CB, Cresswell P, Hsu JC, Laurent-Rolle M, Pavlak JB, Wilen CB, Cresswell P: Enhanced innate immune evasion by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci USA 2021, 118:e210161118.

38. Khaperskyy DA, McCormick C: Timing is everything: coordinated control of host shutoff by influenza A virus NS1 and PA-X proteins. J Virol 2015, 89:6528-6531.

39. Shin D, Mukherjee R, Grewe D, Bokova D, Baek K, Bhattacharya A, Schutz L, Widera M, Mehdioupi AR, Tascher G, et al.: Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020, 587:867-866.

This study unveils preferential targeting of ISG15 conjugation over ubiquitination by SARS-CoV-2 PLpro, and that a PLpro inhibitor can help restore a protective innate immune response to SARS-CoV-2 infection.

40. Gack MU, Albrecht RA, Urano T, Inni KS, Huang IC, Carrero E, Farzan M, Inoue S, Jung JU, Garcia-Sastre A: Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 6:439-445.

41. Rejba R, Albrecht RA, Wang MK, Maharaj NP, Versteeg GA, Nistal-Villan E, Garcia-Sastre A, Gack MU: Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog 2012, 8:e1003059.

42. Liu Y, Qin C, Yao Y, Nge C, Feng JJ, Zhao J, Zhang S, Wang Y, Carriere J, Savas AC, et al.: SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response. mBio 2021, 12:e023352:1.

43. Bergant V, Yamada S, Grass V, Tsukamoto Y, Lavacca T, Krey K, Muhlhofer MT, Wittmann S, Ensser A, Herrmann A, et al.: Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2'-O-ribose methyltransferases. EMBO J 2022, 41:e111608.

This study shows that host 2'-O-ribose methyltransferases can compensate for loss of the SARS-CoV-2 Nsp16 protein function, and that targeting both host and viral methyltransferase activities or the host S-adenosylmethionine cycle enhances SARS-CoV-2 restriction.

44. Hackbart M, Deng X, Baker SC: Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proc Natl Acad Sci USA 2020, 117:8094-8103.

45. Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Carriere J, Savas AC, et al.: Comparative host-cellular protein interaction map reveals pan-viral disease mechanisms. Science 2020, 370:aeeb9403.

46. Varga ZT, Ramos I, Hai R, Schmolke M, Garcia-Sastre A, Hernandez-Sosa A, Palese P: The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 2011, 7:e1002057.

47. Miorin L, Kehrner T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, Copicic A, Makio T, Male M, Morego E, et al.: SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA 2020, 117:28344-28354.

This study provides mechanistic details of SARS-CoV-2 Orf6-mediated blockage of STAT1/2 nuclear translocation and suppression of antiviral ISG expression.

48. Wang S, Dai T, Qin Z, Pan T, Chu F, Lou L, Zhang L, Yang B, Huang H, Lu H, et al.: Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat Cell Biol 2021, 23:715-722.

49. Thome LG, Bouhaddou M, Reusch AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J, Whelan MX, Hossmillo M, Fossati A, et al.: Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature 2022, 502:487-489.

This study unveils that the Alpha variant of SARS-CoV-2 exhibits enhanced immunosuppression by upregulating the expression of subgenomic RNA-encoded viral IFN antagonists; it also provides the first evolutionary evidence of the contribution of nonspike mutations to SARS-CoV-2 immune evasion.

50. Liu Y, Zhang X, Liu J, Xia H, Zou J, Murato AE, Periasamy S, Kurhade C, Plante JA, Bopp NE, et al.: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat Commun 2022, 13:4337.